Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients

Purpose. The prognostic role of serum cancer antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) in breast cancer remains controversial. In this study, we conducted a meta-analysis to investigate the prognostic value of these two markers in breast cancer patients.Methods. After electronic databases were searched, 36 studies (31 including information regarding CA15-3 and 23 including information regarding CEA) with 12,993 subjects were included. Based on the data directly or indirectly from the available studies, the hazard ratios (HRs) and odds ratios (ORs) and their 95% confidence intervals (CIs) were pooled according to higher or lower marker levels.Results. Elevated CA15-3 or CEA was statistically significant with poorer DFS and OS in breast cancer (multivariate analysis of OS: HR = 2.03, 95% CI 1.76–2.33 for CA15-3; HR = 1.79, 95% CI 1.46–2.20 for CEA; multivariate analysis of DFS: HR = 1.56, 95% CI 1.06–1.55 for CA15-3; HR = 1.77, 95% CI 1.53–2.04 for CEA). Subgroup analysis showed that CA15-3 or CEA had significant predictive values in primary or metastasis types and different cut-offs and included sample sizes and even the study publication year. Furthermore, elevated CA15-3 was associated with advanced histological grade and younger age, while elevated CEA was related to the non-triple-negative tumor type and older age. These two elevated markers were all associated with a higher tumor burden.Conclusions. This meta-analysis showed that elevated serum CA15-3 or CEA was associated with poor DFS and OS in patients with breast cancer, and they should be tested anytime if possible.

Download Full-text

Evaluation of clinicopathological features from core needle biopsy and CT imaging as predictors of response to primary systemic therapy for operable breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.11086 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 11086-11086

Author(s):

T. Shien ◽

S. Akashi-Tanaka ◽

C. Shimizu ◽

T. Hojo ◽

K. Seki ◽

...

Keyword(s):

Breast Cancer ◽

Multivariate Analysis ◽

Systemic Therapy ◽

Histological Grade ◽

Breast Conserving Surgery ◽

Clinicopathological Features ◽

Tumor Type ◽

Primary Systemic Therapy ◽

Grade 3

11086 Background: Primary systemic therapy (PST) is standard therapy for patients with locally advanced breast cancer and increasingly used for early-stage operable disease. Clinical and pathologic responses are important prognostic parameters and clinicopathological markers to predict response to PST are needed to individualize treatment. Methods: From 1998 to 2005, 403 primary breast cancer patients were underwent curative surgical treatment after PST (Anthlacycline and/or Taxane) at NCCH. We retrospectively evaluated the clinicopathological features (age, histological type, histological grade, ER, PgR and HER-2) and classification of tumors using CT (localized tumor type and diffused tumor type) at before PST and analyzed the correlation with clinical response and pathological complete response (pCR). The log-rank statistic was used for univariate comparisons and multivariate analysis performed using Cox hazard model. Results: Overall response and pCR rate were 87% and 18%. Breast conserving surgery was performed 37% patients. Histological grade 3 (p<0.0001), ER negative (p<0.0001), PgR negative (p<0.0001), solid-tubular type (p=0.0006), age (>50) (p=0.008) and localized tumor type (p=0.02) correlated with pCR. In multivariate analysis, Histological grade 3 (p=0.01) and localized tumor type (p=0.036) were independent predictors for pCR. ER positive, histological grade 2 or 1, invasive lobular carcinoma and diffuse tumor type associated with low chemosensitivity and low breast conserving surgery rate. Conclusions: Clinical and pathological response significantly associated with ER status and histological grade. Furthermore the classification of tumor type using CT was effective to predict of response to PST. No significant financial relationships to disclose.

Download Full-text

Prognostic significance of the chemokine CXCL13 in node-negative breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.615 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 615-615

Author(s):

Marcus Schmidt ◽

Leonie van de Sandt ◽

Daniel Boehm ◽

Isabel Sicking ◽

Marco Johannes Battista ◽

...

Keyword(s):

Breast Cancer ◽

Cox Regression ◽

Molecular Subtype ◽

Histological Grade ◽

Meta Analysis ◽

Prognostic Significance ◽

Her2 Status ◽

Node Negative ◽

Node Negative Breast Cancer ◽

Independent Prognostic Significance

615 Background: The chemokine CXCL13 is chemotactic for B cells. We examined the prognostic significance of CXCL13 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for CXCL13 (205242_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of CXCL13 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+). Independent prognostic relevance was analysed using multivariate Cox regression. Results: Higher RNA expression of CXCL13 was related to better MFS in a meta-analysis of the whole cohort (HR 0.88, 95% CI 0.83-0.94, P<0.0001). Prognostic significance was most pronounced in the HER2+ positive molecular subtype (HR 0.72, 95% CI 0.59-0.87, P=0.0009) as compared to ER+/HER2- (HR 0.86, 95% CI 0.76-0.98, P=0.0024) and ER-/HER2- (HR 0.85, 95% CI 0.75-0.98), P=0.02) carcinomas of the breast. CXCL13 showed independent prognostic significance (HR 0.81, 95% CI 0.7336 0.8982, P=0.0001) in multivariate analysis. In addition to CXCL13, only histological grade of differentiation (HR 2.20, 95% CI 1.41-3.42, P=0.0005) and tumor size (HR 1.72, 95% CI 1.13-2.61, P=0.012), but neither age nor HER2 status nor hormone receptor status retained an independent prognostic association with MFS. Conclusions: The chemokine CXCL13 has independent prognostic significance in node-negative breast cancer. Higher expression of CXCL13 is associated with improved outcome.

Download Full-text

Prognostic Significance of CD24 and CD44 in Breast Cancer: A Meta-Analysis

The International Journal of Biological Markers ◽

10.5301/jbm.5000224 ◽

2017 ◽

Vol 32 (1) ◽

pp. 75-82 ◽

Cited By ~ 15

Author(s):

Zhu Wang ◽

Qianqian Wang ◽

Qi Wang ◽

Yanping Wang ◽

Jie Chen

Keyword(s):

Breast Cancer ◽

Cancer Progression ◽

Large Scale ◽

Histological Grade ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Stem Cell Marker ◽

Sensitivity Analyses ◽

The Stability

Objective Numerous studies have focused on the prognostic roles of CD24 and CD44 in breast cancer, but the results have been equivocal. The aim of this study was to gain better insight into the relationship between expression of CD24 and of CD44, either alone or in combination, and prognostic parameters in breast cancer. Methods Publications addressing the associations of CD24 or CD44 expression with survival outcome in breast cancer were selected for the meta-analysis according to defined criteria. Studies were pooled and odds ratios (ORs) or hazard ratios (HRs) were calculated. Publication bias and sensitivity analyses were also conducted. Results Sixteen studies comprising 5,697 breast cancer cases were included in our meta-analysis. Overall, CD24 overexpression was significantly associated with histological grade (OR = 1.52; 95% CI 1.12-2.06, p = 0.007), stage (OR = 1.74; 95% CI 1.27-2.40, p<0.001), shortened overall survival (HR = 1.48; 95% CI 1.21-1.80, p<0.001) and disease-free survival (HR 1.45, 95% CI 1.19-1.76, p<0.001), while no such association was observed when we limited our analysis to CD44 and CD44+/CD24- phenotypes. Subgroup analyses for CD24 according to the studies categorized by ethnicity, staining patterns and follow-up period were also conducted, and supported the stability of the prognostic role of CD24. Conclusions Our study demonstrated that the putative stem cell marker CD24 was significantly associated with worse survival based on the obtained data. In particular, CD24 may play a role in tumorigenesis and cancer progression. However, further large-scale studies are needed to confirm these findings.

Download Full-text

THE SIGNIFICANCE OF CEA AND CA15-3 IN EARLY BREAST CANCER ITS ASSOCIATION WITH CLINICO PATHOLOGICAL CHARACTERISTICS A SINGLE-CENTER STUDY IN MADINAH, SAUDI ARABIA

International Journal of Advanced Research ◽

10.21474/ijar01/12103 ◽

2020 ◽

Vol 8 (11) ◽

pp. 1082-1087

Author(s):

Nasser Mulla ◽

◽

Yara Bin Saad ◽

Jamlaa Alharbi ◽

Salwa Alalwi ◽

...

Keyword(s):

Breast Cancer ◽

Carcinoembryonic Antigen ◽

Tumor Markers ◽

Primary Tumor ◽

Elevated Serum ◽

Tumor Grade ◽

Serum Levels ◽

Clinicopathological Characteristics ◽

Cancer Antigen ◽

Cancer Types

Background and Aims: The utility of measuring carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels in patients with breast cancer remains controversial. The present study aims to investigate the association between tumor markers [cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA)] and clinicopathological characteristics. Methods: Serum preoperative CEA and CA 15-3 concentration levels were measured in a total of 135 breast cancer patients.The association of tumor markers levels with clinicopathological characteristics were analyzed. Results: Elevated serum levels of CEA and CA15-3 were identified in 26 (19.26%) and 20 (14.8%) patients, respectively. Increased CEA levels were not associated with age, histological type, tumor size, tumor grade, breast cancer stages, or breast cancer types. CA15-3 levels were positively correlated with the size of the primary tumor (P<0.026) but had no significant correlation with the other factors. Conclusions: The elevation of CA 15-3 was positively correlated with the size of the primary tumor.

Download Full-text

Prognostic and Clinicopathological Value of Cyclin E Expression in Breast Cancer: A Meta-Analysis

10.21203/rs.3.rs-210720/v1 ◽

2021 ◽

Author(s):

Yufei Wang ◽

Qijuan Yang ◽

Deshou Ma ◽

Zhijun Ma ◽

Xiaowu Wang

Keyword(s):

Breast Cancer ◽

Multivariate Analysis ◽

Meta Analysis ◽

Cyclin E ◽

Cochrane Collaboration ◽

Clinicopathological Characteristics ◽

Positive Lymph Node ◽

Cancer Prognosis ◽

Breast Cancer Patients ◽

Cancer Specific Survival

Abstract Background: Multiple studies have analyzed the correlation between Cyclin E and breast cancer prognosis, but the results are controversial. In this study, a meta-analysis was used to summarize the published reports, clarify the predictive value of Cyclin E in breast cancer, and the relationship with clinicopathological characteristics.Methods: A systematic search was retrieved in PubMed, Embase, Web of Science, Cochrane Collaboration Library on the comprehensive search strategy up to 24 August 2020. recurrence-free survival (RFS), overall survival (OS), and breast cancer-specific survival (BCSS) was estimated using pooled hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (95% CIs) by univariate and multivariate analysis.Results: Twenty-eight eligible studies met our inclusion criteria. The present meta-analysis indicates that high cyclin E expression is independently associated with poor OS, BCSS, and RFS in female breast cancer patients by univariate and multivariate analysis. Furthermore, higher histological grades, estrogen receptor (ER)-negativity, positive lymph node metastasis, younger patients, and premenopausal status were associated with Cyclin E overexpression. Conclusions: High expression of Cyclin E is associated with poor breast cancer outcomes and relevant to multiple clinical characteristics.

Download Full-text

Lack of Association between Common Polymorphisms in Selenoprotein P Gene and Susceptibility to Colorectal Cancer, Breast Cancer, and Prostate Cancer: A Meta-Analysis

BioMed Research International ◽

10.1155/2021/6525449 ◽

2021 ◽

Vol 2021 ◽

pp. 1-8

Author(s):

Hanjiang Xu ◽

Fan Mo ◽

Jun Zhou ◽

Zongyao Hao ◽

Xianguo Chen ◽

...

Keyword(s):

Breast Cancer ◽

Prostate Cancer ◽

Colorectal Cancer ◽

Cancer Susceptibility ◽

Meta Analysis ◽

Selenoprotein P ◽

Tumor Type ◽

Cancer Breast ◽

P Gene ◽

Breast And Prostate Cancer

Background and Objective. Selenoprotein P (SEPP1) is the major selenoprotein in plasma. Previous studies have demonstrated that SEPP1 expression was reduced in human prostate and colon tumors. Nowadays, studies concerning SEPP1 gene polymorphisms and cancer susceptibility have been extensively investigated, whereas results from these studies remain debatable rather than conclusive. Thus, we performed the present meta-analysis to comprehensively assess the association between two common polymorphisms (rs3877899 and rs7579) in SEPP1 and cancer susceptibility. Method. We search the PubMed, Embase, Google Scholar, and Wanfang (China) databases (up to December 1, 2020) to identify all eligible publications. The pooled odds ratio (OR) correspondence with 95% confidence interval (CI) was calculated to evaluate the associations. Results. Finally, nine eligible studies with 7,157 cases and 6,440 controls and five studies with 2,278 cases and 2,821 controls were enrolled in rs3877899 and rs7579 polymorphisms, individually. However, a null significant association was detected between the two polymorphisms in SEPP1 and susceptibility to colorectal, breast, and prostate cancer in all comparison models. Subsequently, subgroup analysis based on tumor type, no significant association was identified for prostate, breast, and colorectal cancer. In addition, when the stratification analyses were conducted by the source of control, HWE status, and ethnicity, yet no significant association was found. Conclusions. The current meta-analysis shows that SEPP1 rs3877899 and rs7579 polymorphisms may not be associated with susceptibility to colon cancer, breast cancer, and prostate cancer, and further well-designed studies with a larger sample size are warranted to validate our findings.

Download Full-text

Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis

10.21203/rs.3.rs-337175/v1 ◽

2021 ◽

Author(s):

Guixin Wang ◽

Shuhao Zhang ◽

Meiling Wang ◽

Lin Liu ◽

Yaqian Liu ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Lymph Nodes ◽

Meta Analysis ◽

Prognostic Significance ◽

Axillary Lymph Nodes ◽

Axillary Lymph ◽

Occult Metastases ◽

Node Metastases ◽

Disease Free

Abstract Background: Occult metastases in axillary lymph nodes have been reported to be associated with poor prognosis in patients with breast cancer. However, studies on the prognostic value of occult metastases remain controversial. This meta-analysis aimed to evaluate the prognostic significance of occult lymph node metastases in breast cancer.Methods: Studies published published until May, 2020, which retrospectively examined negative lymph nodes by step sectioning and/or immunohistochemistry, were retrieved from MEDLINE, EMBASE, CNKI, and Cochrane Library. The pooled Relative risk (RR) with 95% confidence interval (95% CI) for overall survival (OS) and disease-free survival (DFS) were calculated to appraise the associations between occult metastases and prognosis.Results: The results showed patients with occult metastases in axillary lymph nodes had poorer five-year DFS (RR = 0.930; 95% CI = 0.907–0.954) and OS (RR = 0.972; 95% CI = 0.954–0.990). Furthermore, the DFS (RR = 0.887; 95% CI = 0.810–0.972) and OS (RR = 0.896; 95% CI = 0.856–0.939) of patients with occult metastases were much lower after a ten-year follow-up.Conclusions: Occult metastases in the axillary lymph nodes of patients with breast cancer are associated with poorer disease-free and overall survival. Occult metastases might serve as a predictive factor of survival outcomes in patients with breast cancer.

Download Full-text

Clinicopathological and Prognostic Significance of CBX3 Expression in Human Cancer: a Systematic Review and Meta-analysis

Disease Markers ◽

10.1155/2020/2412741 ◽

2020 ◽

Vol 2020 ◽

pp. 1-11

Author(s):

Hexin Lin ◽

Xin Zhao ◽

Lu Xia ◽

Jiabian Lian ◽

Jun You

Keyword(s):

Malignant Tumors ◽

Human Cancer ◽

Meta Analysis ◽

Univariate Analysis ◽

Prognostic Significance ◽

Cancer Prognosis ◽

High Expression ◽

Clinicopathological Parameters ◽

Malignant Neoplasms ◽

Tumor Type

Background. Chromebox protein homolog 3 (CBX3) as a member of the heterochromatin-associated protein 1 (HP1) family has been reported to be overexpressed in human cancer tissues. Numerous studies have shown the relationship between the CBX3 expression and clinicopathological factor or prognosis in malignant tumors, but their results are inconsistent. To address these results, a meta-analysis was described to investigate the prognostic value and clinicopathological significance of CBX3 expression in human malignant neoplasms. Methods. PubMed, Web of Science, Embase, and Chinese National Knowledge Infrastructure (CNKI) were used to search eligible literatures, including publications prior to September 2019. The role of CBX3 in cancer prognosis and clinicopathological characteristics was assessed by pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs). Results. Eleven studies with 1682 cancer patients were enrolled in this meta-analysis. This analysis demonstrated that the patients’ increased CBX3 expression was significantly associated with poor overall survival (OS) (univariate analysis: HR = 1.81 , 95% CI 1.46-2.25; multivariate analysis: HR = 1.95 , 95% CI 1.63-2.34). Subgroups analysis by tumor type also indicated that high expression of CBX3 was correlated with poor OS in tongue squamous cell carcinoma ( HR = 3.31 , 95% CI 2.03-5.39), lung cancer ( HR = 1.66 , 95% CI 1.21-2.29), genitourinary cancer ( HR = 2.03 , 95% CI 1.15-3.58), and digestive cancer ( HR = 1.48 , 95% CI 1.23-1.79). For clinicopathological features, high expression of CBX3 was associated with lymph node metastasis ( OR = 2.96 , 95% CI 1.42-6.20) and lager tumor size ( OR = 1.60 , 95% CI 1.12-2.28). Conclusion. The results of this meta-analysis indicated that CBX3 expression may be a novel biomarker for predicting patient prognosis and clinicopathological parameters in multiple human cancer.

Download Full-text

The prognostic significance of preoperative serum albumin in urothelial carcinoma: a systematic review and meta-analysis

Bioscience Reports ◽

10.1042/bsr20180214 ◽

2018 ◽

Vol 38 (4) ◽

Cited By ~ 10

Author(s):

Jing Liu ◽

Fang Wang ◽

Shaohong Li ◽

Wenhui Huang ◽

Yanjuan Jia ◽

...

Keyword(s):

Serum Albumin ◽

Urothelial Carcinoma ◽

Serum Albumin Level ◽

Meta Analysis ◽

Prognostic Significance ◽

Albumin Level ◽

Cochrane Library ◽

Tumor Type ◽

Poor Overall Survival ◽

Preoperative Serum

Preoperative serum albumin has been considered to be closely correlated with the prognosis of various cancers, including urothelial carcinoma (UC). However, to date, this conclusion remains controversial. The aim of this meta-analysis is to investigate the prognostic significance of preoperative serum albumin in UC. A literature search was performed in PubMed, Web of Science, Embase, and Cochrane Library up to 4 July 2017. Herein, a total of 15506 patients from 23 studies were enrolled in our meta-analysis. Decreased preoperative serum albumin level predicted poor overall survival (OS) (HR = 1.88, 95% CI: 1.44–2.45, P<0.0001), cancer-specific survival (CSS) (HR = 2.03, 95% CI: 1.42–2.90, P=0.0001), recurrence-free survival (HR = 1.85, 95% CI: 1.15–2.97, P=0.01), 30-day complications (30dCs) after surgery (odds ratio (OR) = 1.93, 95% CI: 1.16–3.20, P=0.01), and 90-day mortality after surgery (OR = 4.24, 95% CI: 2.20–8.16, P<0.001). The subgroup analyses indicated that low preoperative serum albumin level is still positively associated with a worse prognosis of UC based on ethnicity, cut-off value, tumor type, analyses type, and sample size. Our meta-analysis indicated that reduced preoperative serum albumin level was a predictor of poor prognosis of UC.

Download Full-text

Claudin-1 Is a Valuable Prognostic Biomarker in Colorectal Cancer: A Meta-Analysis

Gastroenterology Research and Practice ◽

10.1155/2020/4258035 ◽

2020 ◽

Vol 2020 ◽

pp. 1-10

Author(s):

Didi Zuo ◽

Jiantao Zhang ◽

Tao Liu ◽

Chao Li ◽

Guang Ning

Keyword(s):

Colorectal Cancer ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Venous Invasion ◽

Lymphatic Invasion ◽

Cochrane Library ◽

Test Sequence ◽

Tumor Type ◽

The Stability

Background. Claudin-1 plays an important part in maintaining the mucosal structures and physiological functions. Several studies showed a relationship between claudin-1 and colorectal cancer (CRC), but its prognostic significance is inconsistent. This meta-analysis assessed the prognostic value and clinical significance of claudin-1 in CRC. Materials and Methods. We retrieved eligible studies from PubMed, Cochrane Library, Embase, and Web of Science databases before February 10, 2020. The hazard ratio (HR) with 95% confidence interval (CI) was applied to assess the correlation between claudin-1 and prognosis and clinical features. Heterogeneity was assessed by the Cochran Q test and I-square (I2), while publication bias was evaluated by the Begg test and Egger test. Test sequence analysis (TSA) was used to estimate whether the included studies’ number is sufficient. The stability of the results was judged by sensitivity analysis. Metaregression was utilized to explore the possible covariance which may impact on heterogeneity among studies. Results. Eight studies incorporating 1704 patients met the inclusion criteria. Meta-analysis showed that the high expression of claudin-1 was associated with better overall survival (HR, 0.46; 95% CI, 0.28–0.76; P=0.002) and disease-free survival (HR, 0.44; 95% CI, 0.29–0.65; P=0.003) in CRC. In addition, we found that claudin-1 was related to the better tumor type (n=6; RR, 0.60; 95% CI, 0.49–0.73; P<0.00001), negative venous invasion (n=4; RR, 0.81; 95% CI, 0.70–0.95; P=0.001), and negative lymphatic invasion (n=4; RR, 0.83; 95% CI, 0.74–0.92; P=0.0009). Conclusion. The increased claudin-1 expression in CRC is associated with better prognosis. In addition, claudin-1 was related to the better tumor type and the less venous invasion and lymphatic invasion.

Download Full-text